

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Afatinib for treating locally advanced or metastatic squamous non-small-cell lung cancer after platinum-based chemotherapy [ID969]**

**Batch 48**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
---

No issues have been identified.
---------------------------------

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
---

N/A
-----

3. Has any change to the draft scope been agreed to highlight potential equality issues?
--

N/A
-----

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
--

Technology Appraisals: Scoping

Equality impact assessment for the single technology appraisal afatinib for treating locally advanced or metastatic squamous non-small-cell lung cancer after platinum-based chemotherapy

Issue date: November 2016

No additional stakeholders have been identified.

**Approved by Associate Director (name):** Helen Knight

**Date:** 10/11/2016